Suárez-Carantoña C, Jiménez-Cauhé J, González-García A, Fernández-Guarino M, Asunción Ballester M
Internal Medicine, Hospital Universitario Ramón y Cajal, Madrid, Spain; Universidad de Alcalá, Alcalá de Henares, Spain.
Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Actas Dermosifiliogr. 2023 Jan;114(1):62-68. doi: 10.1016/j.ad.2021.10.018. Epub 2022 Jul 20.
Low-dose rituximab is a protocol used in several autoimmune diseases, that has also shown to be effective and safe in pemphigus vulgaris.
To study whether low-dose rituximab is also effective for bullous pemphigoid.
Patients with BP were treated with a single cycle of two infusions of rituximab 500mg at an interval of 2 weeks. Early and late end points were monitored.
Six patients, five males and a female, with a mean age of 78.6 years (range 65-89) and a mean history of BP of 6.7 months (range 2-16) were included. A rapid and marked response was observed after a single cycle of treatment, with a mean time to disease control and to end of consolidation phase of 1.9 (range 1-3), and 4 weeks (range 3-5), respectively. Four patients achieved a late end point at a mean of 15.75 weeks (range 13-20). Three of them achieved partial remission with no therapy (two patients) or with minimal therapy (one patient), and one of them achieved complete remission with no therapy. One patient has 6 weeks of clinical follow-up after rituximab administration. The remaining patient relapsed 4 weeks after the rituximab treatment, and remains in complete remission with more than minimal therapy. One patient had a herpetic gingivostomatitis related to rituximab.
Low-dose rituximab for BP achieved acceptable remission rates and steroid-sparing activity, with a better safety profile and a lower cost, compared to standard doses. This pilot study suggests that low-dose rituximab could be a therapeutic option for BP.
